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Non-invasive diagnosis of transthyretin amyloidosis heart involvement using bone scan: a 
retrospective evaluation of 4228 scintigraphies. 
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ABSTRACT 
Amyloidosis is an important cause of infiltrative cardiomyopathy and is often diagnosed lately in the course 
of the disease; radiolabeled bisphosphonates bone scan is highly sensitive in detecting transthyretin (TTR) 
cardiac amyloidosis; data on the true prevalence of cardiac involvement in TTR amyloidosis are lacking. The 
aim of the present retrospective observational, monocentric study was to estimate the prevalence of positive 
bone scan suspect for TTR cardiac amyloidosis in the population of Piedmont - a region in the north-west of 
Italy - retrospectively assessing unexpected cardiac emissions in bone scan scintigraphy among an all-comers 
population who underwent a bone scan at San Luigi Gonzaga University Hospital between January 2015 and 
May 2020. ECG, echocardiography and clinical status of patients with positive cardiac emission have been 
collected in order to better characterize their clinical features.  
   
Background. Amyloidosis is a group of diseases characterized by deposition in human tissues of 
protein aggregates [1]. A subtype of amyloidosis is characterized by accumulation of transtyretin (TTR), either 
in its natural (wild type ATTR amyloidosis, ATTRwt) or mutated (hereditary ATTR amyloidosis, hATTR) 
form. In this disease TTR tetramer, mutated or natural with age, becomes instable and dissociates into single 
monomers [2]. Clinically, the disease causes heart failure, orthostatic hypotension, neurological and autonomic 
dysfunctions, renal insufficiency, carpal tunnel syndrome and lumbar spinal stenosis [3].  
Currently, the diagnosis is based on non-invasive tools [3]: ECG tipically shows low voltages and 
atrial fibrillation, first-degree atrioventricular block, left bundle-branch blocks and infarct-like patterns [4] 
while echocardiography a hypertrophic phenotype with thickness of interventricular septum and posterior 
wall, atrial enlargement, pericardial effusion, diastolic abnormalities and apical sparing [5]. Cardiac Magnetic 
Resonance is a sensitive and specific tool in diagnosing the condition but does not differentiate between TTR 
and other forms of amyloidosis [6] Conversely, bone scan with radiolabeled bisphosphonates, such as 
[99mTc]-HDP or [99mTc]-DPD, able to link calcium of TTR fibrils, has approximately 100% sensitivity for 
detection of myocardial involvement in TTR amyloidosis [7]. Endomyocardial biopsy (EMB), considered the 
gold standard for histological diagnosis, is used only when noninvasive examinations for TTR amyloidosis are 
inconclusive [8].  
Despite an early diagnosis is of paramount importance for the prognosis of these patients, nowadays, 
the average time from symptoms onset to TTR amyloidosis diagnosis is about three years [9]. 
 
Study goals. Data on the true prevalence of cardiac involvement in TTR amyloidosis are lacking. The 
aim of our study was to estimate the prevalence of positive bone scan suspect for TTR cardiac amyloidosis in 
the population of Piedmont - a region in the north-west of Italy - retrospectively assessing unexpected cardiac 
emissions in bone scan scintigraphy among an all-comers population who underwent a bone scan in our centre. 
Moreover, we aimed to analyze the clinical history, electrocardiographic and echocardiographic features of 
patients with positive scans (Perugini score of 2 or 3) in order to describe the phenotypic expression of TTR 
amyloidosis cardiac involvement. 
 
Methods. We conducted a retrospective, observational, monocentric study which included patients by 
analyzing the digital archive of bone scintigraphies performed between January 2015 and May 2020 in the 
Nuclear Medicine Department of AOU San Luigi Gonzaga, Orbassano, Turin, Italy. We included all patients 
who underwent a total-body scintigraphy for any reason. The protocol used in our centre is a whole-body bone 
scan using [99mTc]-HDP or [99mTc]-DPD at the discretion of nuclear doctor. The tracer is administrated 
intravenously at the median dose of 740 MBq. The patients usually only undergo the delayed phase 
examination, 3 hours after the agent’s injection. The results obtained are analyzed for both cardiac and non-
cardiac emissions. In case of cardiac emission, the Perugini score is used.  We collected general demographic 
data, indication to bone scintigraphy, tracer and protocol used and results of the bone scintigraphy including 
any positivity for cardiac uptake from the digital archive of the Nuclear Medicine Department. Hence, patients 
with a positive cardiac uptake (Perugini 2 ore 3) were selected. Personal data in the Cardiology department 
digital database were searched for to obtain all relevant clinical data available, focusing on previous 
cardiovascular history, ECGs and echocardiographic examinations. In the absence of cardiological data, 
patients, or their general practitioners, were contacted. When multiple examinations were present the 
temporally closest to the bone scan was considered. Finally, only for those patients without previous 
cardiovascular evaluation, an in-person visit with ECG and echocardiography scan was arranged. The data 
collected were analyzed using SPSS 25.0 software (IBM, ARMONK, USA) and GraphPad Prism 4 (La Jolla 
California USA). The study was performed according to the Institution Review Board guidance of our centre 
and conducted in accordance to the latest amendments of the Declaration of Helsinki. 
 
Results and discussion. The prevalence of Perugini score 2 or 3 for cardiac involvement of TTR amyloidosis 
was 0.54% (23/4228) in the five year time span included in our analysis. The bone scan was mainly performed 
using [99mTc]-HDP (82.9%) and the dominant indication for the exam was oncological in the 61% of cases. 
The 23 patients (18 men (78%), mean age of 83 ± 5 years, BSA of 1.82 m2 ± 0.15 m2) having a cardiac 
gamma emission, 14 (61%) had a Perugini score of 3. Scan indication was dominantly oncological (11, 47.9%), 
followed by orthopedical (7, 30,1%). Sex and age stratification of patients with positive cardiac uptake is 
reported in Figure 1. The clinical and scintigraphic features are reported, instead, in Table 1.  
Fourteen subjects (60.9%) had arterial hypertension, with mean 126 ± 11.86 mmHg systolic, and 80.2 ± 13.7 
mmHg diastolic BP. One subject had a history of coronary artery disease (4.4%), 3 had a permanent pacemaker 
(13%), 11 suffered a previous episode of heart failure (48%). Eight subjects presented known neuropathy 
(34.8%) and 5 carpal tunnel syndrome (21.7%). Five patients (21.7%) were asymptomatic, with a silent 
cardiovascular history, without arrhythmias or heart failure signs. Hs Troponin I levels, when available 
(missing data for 9 patients), resulted slightly abnormal (69.1 ± 15.2 ng/mL; normal value ≤ 34 ng/ml). Several 
features were revealed at ECG: 6 subjects presented low voltages (26%), 13 atrial fibrillation (55%) and 
conduction disturbances were common (7 first-degree AV blocks (30%), 5 left bundle branch block (22%) and 
4 right bundle branch blocks (17%)). Echocardiogram showed biatrial dilatation (left atrial volume 66.6 ± 18.5 
ml/m2, right atrial volume 52.5 ± 9.3 ml/m2).  The left ventricle was not dilated (telediastolic diameter: 50.4 ± 
5.5 mm; telesistolic diameter: 35.2 ± 6.9 mm) but indexed mass was overall increased (182 ± 25.5 g/m2) due 
to the thickening of interventricular septum (13.1 ± 2 mm) and posterior wall (12.9 ± 1.7 mm). Moreover, the 
left ventricular systolic function was slightly reduced with an ejection fraction (EF) of 49.1 ± 9.3%. None of 
the subjects with positive cardiac uptake presented alterations of the segmental kinesis nor moderate or severe 
valvular heart disease. The mitral E/A ratio was 1.3 ± 0.8 and the average E/E’ of the left ventricle 15.1 ± 6.4. 
The systolic pulmonary artery pressure (PAPs) was 43.9 ± 12.6 mmHg and a mild right ventricle basal 
telediastolic diameter dilatation was, instead, prevalent (45.2 ± 1.5 mm) with a normal right ventricle systolic 
function (tricuspid S’ 12.2 ± 3.9 cm). Full details of the echocardiographical features of our population are 
also reported in Table 1.  
 
The present study, providing a 0.5% prevalence of TTR amyloidosis heart involvement in the 
population of Piedmont, north-west Italy, confirms previous data from Longhi et al showing a 0.36% 
myocardial tracer uptake in an all-comers population undergoing 99mTc-DPD scintigraphies at the Bologna 
University Hospital [10]. TTR amyloidosis is a condition characterized by a long latency period between the 
symptoms onset and the definite diagnosis. Consequently, a positive bone scan with cardiac gamma emissions 
should be considered as a crucial opportunity in order to diagnose the pathology early in the disease course. In 
our case series, bone scan allowed a diagnosis in 5 (21.7%) asymptomatic patients before the onset of 
arrhythmias or heart failure; however, it should be noted that all patients with a positive bone scan defined as 
a Perugini score 2 or 3, showed already a degree of involvement on echocardiography, with at least a mildly 
abnormal left ventricular wall thickness (minimum 12 mm) and a moderately abnormal indexed left ventricular 
mass (minimum 147 g/m2). The diagnosis in a preclinical stage could allow early treatment of the disease, 
potentially improving prognosis of the patients [11]. In fact, during the study period, 6 patients (26%) died.  
Bone scan should, therefore, be considered a useful opportunity in which an early diagnosis can be achieved. 
As a consequence, an in-hospital medical network in which Nuclear Medicine doctors refer patients with a 
positive bone scan for myocardial uptake with a Perugini score of 2 or 3 to cardiologists expert on 
cardiomyopathies surely could contribute to significantly reduce the time to reach diagnosis of heart 
involvement in cardiac amyloidosis starting prognosis modifying therapies. 
 
Study limitation. Our study encompasses several limitations, first of all the retrospective and 
monocentric design of the study; moreover, the patients did not undergo a comprehensive diagnostic workup 
in case of bone scan positivity for cardiac uptake. Important exams such as serum and urinary immunofixation 
and genetic testing were waived not giving the chance to confirm the diagnosis of amyloidosis TTR. Anyway, 
the main purpose of the study was to evaluate the prevalence of cardiac uptake in an all-comers population 
undergoing bone scan for different reasons to estimate cardiac involvement; echocardiography showed 
characteristics compatible with initial amyloidotic involvement in most cases. Finally, some TTR gene 
mutations appear to have a low correlation with bone scan cardiac uptake [12]; as a consequence, an 
underestimation of the true prevalence of TTR amyloidosis heart involvement can not be excluded. 
 
Conclusions. Prevalence of cardiac TTR amyloidosis involvement in an all-comers population 
undergoing bone scan was 0.54%. A positive bone scan (Perugini score 2 or 3) allowed an early, preclinical 
diagnosis in 21.7% of amyloidosis patients, supporting the need of a strong collaboration between nuclear 
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N = 9 
Perugini 3 
N = 14 
p-value 
Age 83.6 ±  5.3 82.6 ±  5.7 0.69 
Men 6 (66.7) 12 (85.7) 0.28 
BSA (Body Surface Area) 1.8 ±  0.07 1.8 ±  0.12 0.38 




























Aortic root 36.0 ±  5.6 35.9 ±  5.3 0.95 
Ascendant aorta 37.1 ±  2.8 37.6 ±  2.9 0.71 
Ascendant aorta (mm/m3) 19.9 ±  2.5 19.4 ±  2.5 0.67 
Left-atrial diameter (mm) 50.3 ± 9.6 51.3 ±  8.3 0.81  
Left-ventricular telediastolic 
diameter (mm) 
51.7 ±  6.3 49.6 ±  4.9 0.89  
Left-ventricular telesistolic 
diameter (mm) 
36.1 ±  7.2 34.6 ±  6.9 0.61  
Right-ventricular basis 
telediastolic diameter (mm) 
46.0 ±  1.5  44.6 ±  1.3  0.03  
Interventricular septum 
diameter (mm) 
13.9 ± 0.9 14.3 ± 1.5 0.49  
Posterior wall diameter (mm) 12.8 ± 1.8 13.1 ± 1.7 0.69  
Left ventricular mass (g) 302.3 ± 50.3 272.8 ±  64.2 0.26  
Left ventricular mass (g/m2) 175.8 ± 27.8 186.7 ±  23.9 0.33 
Right atrial volume (ml/m2) 52.3 ±  9.6 52.6 ±  9.4 0.95  
Left atrial volume (ml/m2) 63.1 ± 10.0 68.9 ± 22.5 0.48  
E/A ratio 1.6 ± 1.1 1.1 ± 0.4 0.11 
Isovolumetric relaxation time 
(msec) 
61.7 ±  9.8 59.7 ± 12.9 0.7 
Mitral E/E’ 17.0 ±  7.8 13.9 ±  5.3 0.83 
Tricuspid S’ 12.4 ±  4.7 12.1 ±  3.5 0.26 
PAPs (mmHg) 45.5 ± 15.9 42.9 ± 10.5 0.64 
Ejection fraction (%) 51.1 ± 10.1 42.9 ± 10.5 0.43 
Aortic stenosis 0 0 - 
Ventricular kinesis 
alterations 
5 (55.6) 7 (50.0) 0.79 


























Prevalence by Sex and Age
PERCENTAGE OF MALES PERCENTAGE OF FEMALES
